Skyhawk’s RNA splicing modifier for Huntington’s disease cleared for Australian trial

Oct. 24, 2023

Skyhawk Therapeutics Inc. has obtained Australian human research ethic committee (HREC) approval to conduct a phase I trial of SKY-0515 for Huntington’s disease.

BioWorld Science Regulatory Neurology/psychiatric Australia

Today's news in brief

BioWorld

BioWorld briefs for March 28, 2025.

FDA says changes in Dexcom G6, G7 sensors constitute misbranding

BioWorld MedTech

The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 28, 2025

CMV history cited in DMD liver death on Sarepta’s Elevidys

BioWorld

Wall Street was weighing the gravity of the death from acute liver failure of a patient who was treated for Duchenne muscular dystrophy (DMD) with Sarepta...

UK government abolishes NHS England

BioWorld MedTech

In a move that surprised many across the health care sector, the U.K. government decided to scrap NHS England, the body which runs the national health service...